Skip to content
Pharma Topics
Pharma Topics
  • Home
  • Blog
  • Forums
  • Calculation
  • About Us
Pharma Topics
  • Home
  • Blog
  • Forums
  • Calculation
  • About Us
  • Forums
  • Audit
  • Automation
  • Bioequivalence
  • Clinical Trial
  • Data Integrity
  • GxP
  • ICH Terms
  • Generic Drug
  • Manufacturing
  • Regulatory Affairs

Welcome to Pharma Topics Forums

The largest online community for industrial pharmacists.
Menu
Forum Navigation
ForumMembersActivityLoginRegister
Forum breadcrumbs - You are here:Pharma ForumProfile: yeodebra3858259
Please Login or Register to create posts and topics.

Profile: yeodebra3858259

yeodebra3858259
User
ProfilePost History
Last seen:
Seen 9 months ago
Member Since:
August 30, 2025
Member Activity
0
Topics Started
0
Replies Created
0
Likes Received

Recent Pharma Topics

Key Parts of DMF to Review

March 20, 2026

EU Market Authorization: A Strategic Decision Tree for Pharma Professionals

March 20, 2026

Difference Between PVC and PVdC Blister Packaging

March 20, 2026

How Do You Choose an RPM in Dissolution?

March 10, 2026

How to Identify Critical Material Attributes (CMAs) of an API in QbD

February 13, 2026

Extent of CMA Evaluation Required for Non-Critical Excipients

February 13, 2026

Statistics Required in Formulation Development

February 13, 2026

A Bioequivalence Lesson Experience

February 13, 2026

Do Pharmacopeial Methods Need Forced Degradation Studies?

February 2, 2026

Does f2 Apply to Modified-Release Dissolution Profiles?

February 2, 2026

Root Cause Analysis in Pharmaceutical Industry

January 30, 2026

Bound Water vs Free Water

January 30, 2026

Computer System Assurance

January 16, 2026

CSV Qualification Summary Report

January 16, 2026

Difference Between 21 CFR Part 11 and Annex 11

January 16, 2026

What is a Non-GxP System?

December 20, 2025

Determining GxP Relevant Software

December 20, 2025

Software Development Life Cycle in Pharmaceutical Industry

December 20, 2025

URS | The Foundation of CSV

December 20, 2025

Is Coning Always a Problem?

December 16, 2025

New Biosimilar Era | FDA’s Biggest Shift

December 12, 2025

Common Technical Document (CTD)

December 12, 2025

Inspection Readiness | From Audit Week to Always-On

December 12, 2025

Understanding D50 in Particle Size Distribution of API – Why It Matters!

November 21, 2025

API Particle Size Distribution (PSD) Matters in Generic Formulations

November 19, 2025

When is a Clinical Endpoint Bioequivalence Study Required?

November 14, 2025

BCS-Based Biowaiver vs. In Vivo Bioequivalence Study

November 14, 2025

Understanding Non-Sink Conditions in Dissolution Testing

November 14, 2025

Discriminatory Dissolution & Q-Point Specification – The Connection

November 14, 2025

API/Drug Substance Selection in Generic Development – Key Points

November 4, 2025

Reactive Impurities in Pharmaceutical Excipients

November 3, 2025

API Impurity Specification

November 3, 2025

Pharmacomicrobiomics

November 3, 2025

Lean Six Sigma and QbD

September 29, 2025

Relationship Between QTPP and CQA

September 29, 2025

Quality Target Product Profile (QTPP) in Pharmaceutical Development

September 29, 2025

Lean Six Sigma in Pharmaceutical Formulation Development – A Practical Perspective

September 29, 2025

Isolators in Pharma Industry

August 16, 2025

Disinfection vs. Sterilization

August 16, 2025

Stability Study in Pharma

August 16, 2025

Online Partners

PHARMADIGESTS.COM

NAPLEXSTUDY.COM

PHARMASPECIALISTS.COM

INDUSTRIALPHARMACIST.COM

Important Topics

  • Analytical Pharmacy Topics
  • Formulation Development Topics
  • Pharmaceutical Manufacturing Topics
  • Quality Control Topics
  • Quality Assurance Topics
  • Regulatory Affairs Topics
  • Glossary of ICH Terms

Contact Us

Have you any questions, feedback, or suggestions?

Reach out to us at: [email protected]

We value your input and strive to improve every day.

  • About Us
  • DMCA
  • Privacy Policy
© 2024 PharmaTopics.com | All Rights Reserved.